Download PDF
Thromb Haemost 1984; 51(02): 157-164
DOI: 10.1055/s-0038-1661049
Original Article
Schattauer GmbH Stuttgart

Stanozolol-Induced Changes in Fibrinolysis and Coagulation in Healthy Adults

C Kluft
1   The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
F E Preston
2   The University Department of Haematology, Royal Hallamshire Hospital, Sheffield, U. K
,
R G Malia
2   The University Department of Haematology, Royal Hallamshire Hospital, Sheffield, U. K
,
R M Bertina
3   The Haemostasis and Thrombosis Research Unit, Leiden University Hospital, Leiden, The Netherlands
,
G Wijngaards
1   The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
M Greaves
2   The University Department of Haematology, Royal Hallamshire Hospital, Sheffield, U. K
,
J H Verheijen
1   The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
G Dooijewaard
1   The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 02 September 1983

Accepted 27 December 1983

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effects of orally-administered stanozolol, 5 mg b. d. on fibrinolysis, coagulation and on various haematological and biochemical parameters have been studied in 16 healthy adults, 8 males and 8 females. Statistically significant enhancement of extrinsic (tissue-type) plasminogen activator activity was detected in all subjects studied. This was associated with significant increases in plasma plasminogen and a concomitant reduction in histidine-rich glycoprotein. There were no changes in plasma urokinase activity. Changes in the coagulation system included significant reduction in plasma fibrinogen and elevation of protein C and anti thrombin III. Changes in plasma lipids included significant reduction of HDL cholesterol associated with an increase in LDL triglycerides. No change occurred in total cholesterol. There were no major differences between the sexes, nor were there serious side effects.

The effects of stanozolol on extrinsic (tissue-type) plasminogen activator activity, “free” plasminogen, protein C and antithrombin III, argue strongly in favour of its therapeutic potential.

Keywords

Stanozolol - Fibrinolysis - Coagulation
 

  • References

  • 1 Preston FE, Burakowski BK, Porter NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22: 543-551
    CrossrefPubMedGoogle Scholar
  • 2 Davidson JF, Lockhead M, McDonald GA, McNicol GP. Fibrinolytic enhancement by stanozolol: a double-blind trial. Br J Haematol 1972; 22: 543-559
    CrossrefPubMedGoogle Scholar
  • 3 Cunliffe WJ, Dodman B, Roberts BE, Tebbs EM. Clinical and laboratory double-blind investigation of fibrinolytic therapy in cutaneous vasculitis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 325-332
    Google Scholar
  • 4 Jarrett PE, Morland M, Browse NL. Treatment of Raynaud’s phenomenon by fibrinolytic enhancement. Br Med J 1978; 2: 523-525
    CrossrefPubMedGoogle Scholar
  • 5 Bumard K, Clemenson G, Morland M, Jarrett PE, Browse NL. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. Br Med J 1980; 280: 7-11
    CrossrefPubMedGoogle Scholar
  • 6 Walker ID, Davidson JF. Long-term fibrinolytic enhancement with anabolic steroid therapy: a five year study. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1978. 3 491-499
    Google Scholar
  • 7 Jarrett PE M, Morland M, Browse NL. Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement. Br Med J 1977; 1: 933-934
    CrossrefPubMedGoogle Scholar
  • 8 Fiessinger JN, Aiach M. Stanozolol treatment in an AT III deficient patient. Thromb Haemostas 1980; 43: 183
    PubMedGoogle Scholar
  • 9 Kwaan HC, Robbins KC, Wohl RC. Enhancement of plasma plasminogen level by stanozolol in man. Thromb Haemostas 1981; 46: 114 (Abstr)
    PubMedGoogle Scholar
  • 10 Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181-187
    CrossrefPubMedGoogle Scholar
  • 11 Agostoni A, Cicardi M, Martignoni GC, Bergamaschini L, Marasini B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980; 65: 75-79
    CrossrefPubMedGoogle Scholar
  • 12 Warm AP, Greaves MW, Gatecliff M, Williamson DM, Warin RP. Treatment of hereditary angioedema by low dose attenuated androgens: disassociation of clinical response from levels of C1-esterase inhibitor and C4. Br J Dermatol 1980; 103: 405-409
    CrossrefPubMedGoogle Scholar
  • 13 Walker ID, Davidson JF, Young P, Conkie JA. Plasma antithrombin III levels and plasma fibrinolytic activity following oral anabolic steroid therapy. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 85-95
    Google Scholar
  • 14 Nieuwenhuizen W, Wijngaards G, Groeneveld E. Fluorogenic peptide amide substrates for the estimation of plasminogen activators and plasmin. Anal Biochem 1977; 83: 143-148
    CrossrefPubMedGoogle Scholar
  • 15 Vogelaar EF, Brummelhuis AG J, Krijnen HW. Contribution to the optimal use of human blood. III. Large scale preparation of human C1-esterase inhibitor concentrate for clinical use. Vox Sang 1974; 26: 118-127
    CrossrefPubMedGoogle Scholar
  • 16 Brakman P. Fibrinolysis. A standardized fibrin plate method and a fibrinolytic assay of plasminogen (Thesis) Scheltema & Holkema; Amsterdam: 1967
    Google Scholar
  • 17 Rijken DC, Wijngaards G, Welbergen J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 1981; 97: 477-486
    PubMedGoogle Scholar
  • 18 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1976. 2 57-65
    Google Scholar
  • 19 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Pathol 1958; 11: 403-405
    CrossrefPubMedGoogle Scholar
  • 20 Haverkate F, Brakman P. Fibrin plate assay. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 151-159
    Google Scholar
  • 21 Kluft C. C1-inactivator resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135-151
    CrossrefPubMedGoogle Scholar
  • 22 Kluft C, Jie AF H, Allen RA. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood. Thromb Haemostas 1983; 50: 518-523
    PubMedGoogle Scholar
  • 23 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator, applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 24 Wijngaards G, Kluft C, Groeneveld E. Demonstration of urokinase- related fibrinolytic activity in human plasma. Br J Haematol 1982; 51: 165-169
    CrossrefPubMedGoogle Scholar
  • 25 Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
    PubMedGoogle Scholar
  • 26 Kluft C, Jie AF H. Interaction between the extrinsic and intrinsic systems of fibrinolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Cêpelák V, Samama MM, Desnoyers PC. (Eds) Churchill Livingstone; Edinburgh: 1979. 4 25-31
    Google Scholar
  • 27 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic peptide substrate. Scully M, Kakkar VV. (Eds) Churchill Livingstone; Edinburgh: 1979: 128-139
    Google Scholar
  • 28 Kluft C, Vellenga E, Brommer E JP, Wijngaards G. A familial haemorrhagic diathesis in a dutch family: an inherited deficiency of α2- antiplasmin. Blood 1982; 59: 1169-1180
    PubMedGoogle Scholar
  • 29 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-53
    CrossrefPubMedGoogle Scholar
  • 30 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of human plasma protein with affinity for lysine binding sites in plasminogen. J Biol Chem 1980; 255: 10214-10222
    PubMedGoogle Scholar
  • 31 Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemostas 1982; 48: 283-285
    PubMedGoogle Scholar
  • 32 Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477-501
    PubMedGoogle Scholar
  • 33 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 34 Bertina RM, Broekmans AW, Van der Linden IK, Mertens K. Protein C deficiency in a dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5
    PubMedGoogle Scholar
  • 35 Bertina RM, Veltkamp JJ. A genetic variant of factor IX with decreased capacity for Ca2+binding. Br J Haematol 1979; 42: 623-635
    CrossrefPubMedGoogle Scholar
  • 36 Bertina RM, Orlando M, Tiedemann-Alderkamp GH J. Preparation of a human factor VII deficient plasma. Thromb Res 1978; 13: 537-541
    CrossrefPubMedGoogle Scholar
  • 37 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-95
    PubMedGoogle Scholar
  • 38 Dooijewaard G, Kluft C. Contact activation patterns of human plasma measured with a fluorogenic substrate. In: Kinins III: Advances in Experimental Medicine and Biology. Fritz H, Back N, Dietze G, Haberland GL. (Eds) Plenum Press; New York: 1983. 156A 115-120
    Google Scholar
  • 39 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by simple radial immunodiffusion. Immunochemistry 1965; 2: 235-240
    CrossrefPubMedGoogle Scholar
  • 40 Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens. J Clin Endocrinol Metabol 1972; 17: 261-267
    PubMedGoogle Scholar
  • 41 Isacson S, Nilsson IM. Effect of treatment with combined phenformin and ethyloestranol on the coagulation and fibrinolytic systems. Scand J Haematol 1970; 7: 404-408
    PubMedGoogle Scholar
  • 42 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 122-128
    PubMedGoogle Scholar
  • 43 Meade TW, North WR S, Chakrabarti R, Stirling Y, Yames AP, Thompson SG, Brozovic M. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980; 1: 1050-1054
    PubMedGoogle Scholar
  • 44 Holland D, Sotto JJ, Berthier R, Leger J, Michallet M. High rate of long term survivals in AML treated by chemotherapy and androgenotherapy. Cancer 1980; 45: 1540-1548
    CrossrefPubMedGoogle Scholar
  • 45 Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopaenic purpura. N Engl J Med 1983; 308: 1396-1399
    CrossrefPubMedGoogle Scholar
  • 46 Miller NE, Hammett F, Saltisse S, Rao S, Van Zeller H, Coltart J, Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 1981; 282: 1741-1744
    CrossrefPubMedGoogle Scholar
  • 47 Albers JJ, Cheung MC, Hazzard WR. High density lipoproteins in myocardial infarction survivors. Metabolism 1978; 27: 479-485
    CrossrefPubMedGoogle Scholar
  • 48 Kuusi T, Saarinen P, Nikkila E. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2in man. Atherosclerosis 1980; 36: 589-593
    CrossrefPubMedGoogle Scholar
  • 49 Tikkanen MJ, Nikkila EA, Kuusi T, Sipinen S. Different effects of two progestins on plasma high density lipoproteins (HDL2) and postheparin plasma hepatic lipase activity. Atherosclerosis 1981; 40: 365-369
    CrossrefPubMedGoogle Scholar